恢复心肌肌球蛋白轻链激酶改善收缩功能障碍
本研究探究cMLCK失调是否导致心功能障碍,以及恢复cMLCK能否成为收缩性心衰的新型肌力治疗。通过构建MYLK3移码突变敲入小鼠和患者来源iPSC-CMs,发现cMLCK表达降低导致MLC2v磷酸化减少和收缩功能障碍,伴超松弛/无序松弛比例增加;恢复cMLCK或使用新小分子激活剂LEUO-1154可改善收缩功能。
要点
- cMLCK剂量依赖性降低导致小鼠收缩功能障碍
- 恢复cMLCK可改善突变小鼠和iPSC-CMs的收缩功能
- LEUO-1154作为cMLCK激活剂可恢复收缩力而不影响钙瞬变
核心结论
- cMLCK失调导致人类收缩性心功能障碍,恢复cMLCK活性可作为晚期收缩性心衰新型肌力治疗的基础。
研究设计与样本
- 构建携带MYLK3移码突变(c.1951-1G>T; p.P639Vfs*15)的敲入小鼠(Mylk3+/fs和Mylk3fs/fs)及患者来源iPSC-CMs,并开发新型cMLCK小分子激活剂LEUO-1154。
主要发现
- Mylk3+/fs和Mylk3fs/fs小鼠因无义介导的mRNA衰减导致cMLCK表达降低、MLC2v磷酸化减少,呈cMLCK剂量依赖性收缩功能障碍。
- 突变小鼠心肌超松弛/无序松弛状态比例增加,可能贡献于收缩力受损。
- 通过AAV9_MYLK3载体补充cMLCK可挽救敲入小鼠表型。
- MYLK3+/fs iPSC-CMs的cMLCK表达降低50%并出现收缩功能障碍,伴超松弛/无序松弛比例增加;CRISPR基因校正或AAV9_MYLK3补充可恢复。
- LEUO-1154使人类cMLCK对MLC2v磷酸化的Vmax增加约2倍而不影响Km;处理突变iPSC-CMs可恢复MLC2v磷酸化水平和超松弛/无序松弛比例,改善收缩力而不影响钙瞬变。
临床怎么用
- 恢复cMLCK活性可能成为晚期收缩性心衰的新型肌力治疗方法。
- cMLCK激活剂LEUO-1154通过肌力调节机制改善收缩功能而不影响钙瞬变,提示其作为肌力治疗药物的潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cardiac-specific myosin light chain kinase (cMLCK), encoded by MYLK3, regulates cardiac contractility through phosphorylation of ventricular myosin regulatory light chain. However, the pathophysiological and therapeutic implications of cMLCK in human heart failure remain unclear. We aimed to investigate whether cMLCK dysregulation causes cardiac dysfunction and whether the restoration of cMLCK could be a novel myotropic therapy for systolic heart failure. METHODS: We generated the knock-in mice (Mylk3+/fs and Mylk3fs/fs) with a familial dilated cardiomyopathy-associated MYLK3 frameshift mutation (MYLK3+/fs) that had been identified previously by us (c.1951-1G>T; p.P639Vfs*15) and the human induced pluripotent stem cell-derived cardiomyocytes from the carrier of the mutation. We also developed a new small-molecule activator of cMLCK (LEUO-1154). RESULTS: Both mice (Mylk3+/fs and Mylk3fs/fs) showed reduced cMLCK expression due to nonsense-mediated messenger RNA decay, reduced MLC2v (ventricular myosin regulatory light chain) phosphorylation in the myocardium, and systolic dysfunction in a cMLCK dose-dependent manner. Consistent with this result, myocardium from the mutant mice showed an increased ratio of cardiac superrelaxation/disordered relaxation states that may contribute to impaired cardiac contractility. The phenotypes observed in the knock-in mice were rescued by cMLCK replenishment through the AAV9_MYLK3 vector. Human induced pluripotent stem cell-derived cardiomyocytes with MYLK3+/fs mutation reduced cMLCK expression by 50% and contractile dysfunction, accompanied by an increased superrelaxation/disordered relaxation ratio. CRISPR-mediated gene correction, or cMLCK replenishment by AAV9_MYLK3 vector, successfully recovered cMLCK expression, the superrelaxation/disordered relaxation ratio, and contractile dysfunction. LEUO-1154 increased human cMLCK activity ≈2-fold in the Vmax for ventricular myosin regulatory light chain phosphorylation without affecting the Km. LEUO-1154 treatment of human induced pluripotent stem cell-derived cardiomyocytes with MYLK3+/fs mutation restored the ventricular myosin regulatory light chain phosphorylation level and superrelaxation/disordered relaxation ratio and improved cardiac contractility without affecting calcium transients, indicating that the cMLCK activator acts as a myotrope. Finally, human myocardium from advanced heart failure with a wide variety of causes had a significantly lower MYLK3/PPP1R12B messenger RNA expression ratio than control hearts, suggesting an altered balance between myosin regulatory light chain kinase and phosphatase in the failing myocardium, irrespective of the causes. CONCLUSIONS: cMLCK dysregulation contributes to the development of cardiac systolic dysfunction in humans. Our strategy to restore cMLCK activity could form the basis of a novel myotropic therapy for advanced systolic heart failure.
引用
- Hitsumoto T, Tsukamoto O, Matsuoka K, et al. Restoration of Cardiac Myosin Light Chain Kinase Ameliorates Systolic Dysfunction by Reducing Superrelaxed Myosin. Circulation. 2023. PMID: 37128901. doi:10.1161/CIRCULATIONAHA.122.062885
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。